30 closest matches · ranked by relevance
Cardiovascular Diseases · Heart Diseases · Myocardial Infarction
Primary: Number of Patients That Had a First Occurrence of the Primary End Point (Composite of Death From Any Cause, Nonfatal MI, or Class IV HF) — 230; 219 participants
Total Atherosclerotic Occlusion of Femoral Artery
Primary: Primary Safety Endpoint — 2 Percent of participants
Chronic Total Occlusion
Primary: Composite Rate of Major Adverse Events — 3.3 percentage of participants
Peripheral Artery Disease · PAD · Claudication
Primary: Rate of Clinically Driven Target Lesion Revascularization (TLR) — 4.0; 8.2 % probablity of clinically driven TLR
Peripheral Artery Disease
Primary: Percentage of Subjects With Acute Device Success — 55 Participants
Coronary Artery Disease · Coronary Artery Chronic Total Occlusion
Primary: Procedure Success — 119 Participants
Coronary Artery Disease
Primary: Primary Safety Endpoint: 30-Day Freedom From Major Adverse Cardiac Events (MACE) — 89.6 Percent probability of Freedom from MACE
Peripheral Artery Disease
Primary: Efficacy - Number of Subjects That Met Primary Patency Criteria at 12 Months — 120 Participants
Peripheral Vascular Diseases
Primary: Efficacy: Primary Patency at Three Years — 24.2; 25.9 percentage of subjects
Peripheral Artery Disease
Primary: Change in Minimal Luminal Area — 5.8; 4 mm^2
Peripheral Artery Disease · Peripheral Vascular Disease
Primary: Major Adverse Event (MAE) — 0.0; 0.0; 0.0 percentage of participants
Peripheral Artery Disease
Primary: Maximum Walking Time From the Gardner Graded Treadmill Protocol — 117.7; 197.5; 188; 339.9 Seconds
Peripheral Arterial Disease
Primary: Technical Success — 144 lesion
Peripheral Vascular Disease
Primary: Major Adverse Event (MAE) Rate — 11.0 percentage of participants
Peripheral Artery Disease
Primary: Safety Endpoint: Number of Participants With Freedom From Major Adverse Events — 110 Participants
Peripheral Artery Disease
Primary: Change in WIQ Distance Subscore — 22.7; -7.2 Scale units
Peripheral Arterial Occlusive Disease
Primary: Complete Healing of Ischemic Necroses and Ulcerations at 12 Weeks After the End of Study Drug Treatment — 49; 43; 27; 30 participants — p=0.2587
Superficial Femoral Artery Disease
Primary: 12-month Primary Patency Rate — 143; 72 participants — p=0.437
Peripheral Arterial Disease
Primary: Efficacy - Number of Participants With Freedom From MALE at 6 Months and POD at 30 Days — 200 Participants
Peripheral Vascular Disease
Primary: Major Adverse Event (MAE) Rate — 6.1 percentage of participants
Peripheral Vascular Diseases · Claudication
Primary: Primary Patency — 67.7 Percentage of participants with data
Tourniquet Hypertension · Intraoperative Hypertension · Total Ankle Arthroplasty
Primary: Number of Subjects Experiencing Tourniquet Hypertension — 5; 14 Participants
Acute Peripheral Arterial Occlusion
Primary: The Proportion of Subjects With >50% Thrombolysis — 43.8; 47.4; 81.0; 47.4 percentage of participants
PAD · Vascular Calcification
Primary: Device Success — 42; 39 Drug Coated Balloons
Peripheral Vascular Disease
Primary: Major Adverse Event (MAE) — 5.4 percentage of participants
Patency of the Radial Artery
Primary: Number of Patients With Radial Artery Occlusion — 3; 0 Participants
Peripheral Arterial Disease
Primary: Number of Treated Lesions With Achievement of ≤ 50% Residual Stenosis Without Adjunctive Therapy — 3 lesion
Peripheral Arterial Disease · Peripheral Vascular Disease
Primary: Primary Efficacy Endpoint - Mean Reduction in Percent Stenosis — 39 Participants
Critical Limb Ischemia
Primary: To Determine Platelet Inhibition Before and After Switching for Two Weeks From Clopidogrel to Ticagrelor in Patients With CLI. — 173; 140; 71; 63 P2Y12 reaction units…
Atherosclerosis of Native Arteries of the Extremities
Primary: Primary Patency — 94.4 percentage of lesions